Navigation Links
RetireSafe Urges Support for Provenge Prostate Cancer Treatment

BALTIMORE, Nov. 17, 2010 /PRNewswire-USNewswire/ -- RetireSafe, a 400,000-supporter strong national advocacy group for older Americans, today urged the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to support the full reimbursement of costs related to the important new Provenge treatment procedure for prostate cancer patients. RetireSafe President Thair Phillips urged the Committee to "consider not only the many Americans suffering from prostate cancer, and their families, but also the millions of older Americans who are not yet directly affected by the disease, but who will, nonetheless, be affected by this decision." He said, "These seniors care very deeply about the suffering and choices of the individuals who do have prostate cancer and also about the role of government in determining the availability of the best possible medical treatment."

"The MEDCAC decision today will have a lasting effect on future research and development of innovative new medications," Phillips continued. "If the Provenge treatment is denied for reimbursement, future innovation will suffer along with millions of cancer patients," he said.  "We second Dr. Allen Lichter, head of the American Society of Clinical Oncology, that it is 'extremely chilling' to innovation in cancer research if new FDA-approved treatments against cancer must now go through a second round of efficacy and safety review from CMS, even for 'on-label' use," Phillips stated.  "That kind of rationing, after the 15-year, $1 billion development of this state-of-the-art treatment, would be beyond cruel," Phillips charged.

"The clinical effectiveness of the Provenge treatment is not in dispute," he added.   "Whether the MEDCAC admits it or not the real core of this discussion is price, and price is the very thing that should not be a point of discussion," he stated.

"Finally, we see many new Food and Drug Administration (FDA) approved drugs and treatments applauded, while others, like the Provenge treatment for prostate cancer, are attacked for supposedly being too costly," he said. "This apparent bias is troubling to seniors and serves to break the trust seniors have in the agency that has a huge impact on their everyday lives," Phillips went on to say. "This decision impacts not only prostate patients but every American, especially older Americans, and MEDCAC should carefully consider the far reaching implications of this landmark decision," he concluded.

SOURCE RetireSafe
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RetireSafe Announces Intention to Key Vote Senator Dorgans Drug Importation Amendment (SA 2793)
2. RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgans Drug Importation Plan Puts Seniors at Risk
3. DC Patients Cooperative Urges Changes to the Proposed Medical Cannabis Marijuana Regulations
4. Millennium Laboratories, Inc. Urges Medicare to Reconsider the 2010 Physician Reimbursement for Point-of-Care Urine Drug Screen Devices
5. FRC Urges FDA to Reject New Abortion Drug Falsely Labeled as an Emergency Contraceptive
6. HCD Research Executive Urges Pharmaceutical Industry to Leverage Social Media to Enhance Traditional Marketing Research
7. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
8. DEP Urges Medical Facilities to Take Proper Precautions With X-Ray Equipment to Avoid Health Hazards
9. OrthoWorx Urges Warsaws Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland
10. Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans
11. Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Therapeutic Drug Monitoring ... Forecasts, Competitive Intelligence, Emerging Opportunities"  report ... ) has announced the addition ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into ... Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
(Date:11/26/2015)... ... 26, 2015 , ... WorldCare International, Inc., the first company ... Employee Benefits Conference. The Employee Benefits Conference was hosted by the International Foundation ... 11th, 2015. The conference was held at the Hawaii Convention Center in Honolulu, ...
Breaking Medicine News(10 mins):